⚡️🇺🇸#QSR #отчетность
Restaurant Brands International Inc. Reports Second Quarter 2021 Results
Q2 Non-GAAP EPS of $0.77 beats by $0.16;
GAAP EPS of $0.84 beats by $0.24.
Revenue of $1.44B (+37.1% Y/Y) beats by $70M.
Adjusted EBITDA of $577M vs. estimate of $526.2M;
Comparable sales: Tim Horton's 27.6 % vs. estimate of +27.4%; Burger King 18.2 % vs. estimate of +15.6%; Popeyes (0.3) % vs. estimate of +2.86%
Restaurant Brands International Inc. Reports Second Quarter 2021 Results
Q2 Non-GAAP EPS of $0.77 beats by $0.16;
GAAP EPS of $0.84 beats by $0.24.
Revenue of $1.44B (+37.1% Y/Y) beats by $70M.
Adjusted EBITDA of $577M vs. estimate of $526.2M;
Comparable sales: Tim Horton's 27.6 % vs. estimate of +27.4%; Burger King 18.2 % vs. estimate of +15.6%; Popeyes (0.3) % vs. estimate of +2.86%
⚡️🇺🇸#CAT #отчетность
Caterpillar Reports Second-Quarter 2021 Results
Revenue: USD12.9B (est USD12.09B)
Adj EPS: USD2.60 (est USD2.40)
Machinery Transportation Sales: USD12.19B
Operating Profit Margin: 13.9%
Caterpillar Reports Second-Quarter 2021 Results
Revenue: USD12.9B (est USD12.09B)
Adj EPS: USD2.60 (est USD2.40)
Machinery Transportation Sales: USD12.19B
Operating Profit Margin: 13.9%
⚡️🇺🇸#CL #отчетность
Colgate Announces 2nd Quarter 2021 Results
Q2 Non-GAAP EPS of $0.80 in-line;
GAAP EPS of $0.83 beats by $0.03.
Revenue of $4.26B (+9.5% Y/Y) beats by $20M.
Colgate Announces 2nd Quarter 2021 Results
Q2 Non-GAAP EPS of $0.80 in-line;
GAAP EPS of $0.83 beats by $0.03.
Revenue of $4.26B (+9.5% Y/Y) beats by $20M.
⚡️🇺🇸#PG #отчетность
Procter & Gamble Announces Fourth Quarter and Fiscal Year 2021 Results
Revenue: USD18.95B (est USD18.43B)
Core EPS: USD1.13 (est USD1.09)
Sees 2022 Core EPS Growth: +3 To +6%
Q4 Organic Revenue: +4% (est +3.04%)
Sees 2022 Organic Revenue: +2% To +4% (est 2.99%)
Procter & Gamble Announces Fourth Quarter and Fiscal Year 2021 Results
Revenue: USD18.95B (est USD18.43B)
Core EPS: USD1.13 (est USD1.09)
Sees 2022 Core EPS Growth: +3 To +6%
Q4 Organic Revenue: +4% (est +3.04%)
Sees 2022 Organic Revenue: +2% To +4% (est 2.99%)
⚡️💥🇺🇸#BMY
Opdivo (nivolumab) от Bristol Myers Squibb одобрен в ЕС
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy
Opdivo (nivolumab) от Bristol Myers Squibb одобрен в ЕС
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy
⚠️🇺🇸#корпораты #инфляция #сша
Procter & Gamble сетует на рост инфляции
P&G Warns of Higher Costs and Slower Sales
P&G CEO Says Costs of Commodities and Freight Have 'Escalated Significantly'
Procter & Gamble сетует на рост инфляции
P&G Warns of Higher Costs and Slower Sales
P&G CEO Says Costs of Commodities and Freight Have 'Escalated Significantly'
This media is not supported in your browser
VIEW IN TELEGRAM
⚡️🇺🇸#XOM #отчетность
ExxonMobil Corp Q221 Earnings:
Revenue: USD67.74B (est USD61.94B)
Adj EPS: USD1.10 (est USD0.97)
Production: 3.582M BOE/D (est: 3.683M)
Upstream Earnings: USD3.19B (est USD3.05B)
Downstream Loss: USD227M (est Loss: USD155.6M)
Exxon posts highest profit in more than a year
ExxonMobil Corp Q221 Earnings:
Revenue: USD67.74B (est USD61.94B)
Adj EPS: USD1.10 (est USD0.97)
Production: 3.582M BOE/D (est: 3.683M)
Upstream Earnings: USD3.19B (est USD3.05B)
Downstream Loss: USD227M (est Loss: USD155.6M)
Exxon posts highest profit in more than a year
⚡️🇺🇸#CBOE #отчетность
Cboe Global Markets Reports Results for Second Quarter 2021
Q2 Non-GAAP EPS of $1.38 beats by $0.02;
GAAP EPS of $0.98 misses by $0.15.
Revenue of $350.6M (+18.1% Y/Y) beats by $3.96M.
#прогноз FY2021 guidance: Recurring non-transaction revenue is now expected to increase by 15 to 16 percent, from a base of $342 million in 2020, up from previous guidance of 11 to 12 percent, with organic growth targeted in a range of 12 to 13 percent versus previous guidance of 10 to 11 percent.
Cboe Global Markets Reports Results for Second Quarter 2021
Q2 Non-GAAP EPS of $1.38 beats by $0.02;
GAAP EPS of $0.98 misses by $0.15.
Revenue of $350.6M (+18.1% Y/Y) beats by $3.96M.
#прогноз FY2021 guidance: Recurring non-transaction revenue is now expected to increase by 15 to 16 percent, from a base of $342 million in 2020, up from previous guidance of 11 to 12 percent, with organic growth targeted in a range of 12 to 13 percent versus previous guidance of 10 to 11 percent.
🇷🇺#VTBR #отчетность #прогноз
ВТБ НЕ БУДЕТ СЕРЬЕЗНО ПОВЫШАТЬ ТАРГЕТ ПО ПРИБЫЛИ НА 2022 ГОД, ПРЕДУСМОТРЕННЫЙ СТРАТЕГИЕЙ В 310 МЛРД РУБ - ЧЛЕН ПРАВЛЕНИЯ - ПРАЙМ
ВТБ НЕ БУДЕТ СЕРЬЕЗНО ПОВЫШАТЬ ТАРГЕТ ПО ПРИБЫЛИ НА 2022 ГОД, ПРЕДУСМОТРЕННЫЙ СТРАТЕГИЕЙ В 310 МЛРД РУБ - ЧЛЕН ПРАВЛЕНИЯ - ПРАЙМ